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Objectives This study sought to assess the impact of permanent pacemaker (PPM) implantation on clinical outcomes
among patients undergoing transfemoral transcatheter aortic valve implantation (TAVI).
Background TAVI is associated with atrioventricular-conduction abnormalities requiring PPM implantation in up to 40%
among patients treated with self-expanding prostheses.
Methods Between 2007 and 2010, 353 consecutive patients (mean age: 82.6  6.1 years, log EuroSCORE: 25.0 
15.0%) with severe aortic stenosis underwent transfemoral TAVI at 2 institutions. Clinical outcomes were com-
pared among 3 groups: (1) patients requiring PPM implantation after TAVI (PPM after TAVI), (2) patients without
PPM before or after TAVI (no PPM), and (3) patients with PPM before TAVI (PPM before TAVI). The primary end-
point was all-cause mortality at 12 months, and an age-, sex-, and origin-matched standardized population
served as controls.
Results Of 353 patients, 98 patients (27.8%) belonged to the PPM after TAVI group, 48 patients (13.6%) belonged to
the PPM before TAVI group, and 207 patients (58.6%) belonged to the no PPM group. The PPM before TAVI pa-
tients had a significantly higher baseline risk compared with the PPM after TAVI and no PPM patients (coronary
artery disease: 77.1% vs. 52.7% and 58.2%, respectively, p  0.009; atrial fibrillation: 43.8% vs. 22.7% and
20.4%, respectively, p  0.005). At 12 months of follow-up, all-cause mortality was similar in all 3 groups (PPM
after TAVI group: 19.4%, PPM before TAVI group: 22.9%, no PPM group: 18.0%) in unadjusted analyses (p 
0.77) and adjusted analyses (p  0.90). Compared with the standardized population, adjusted hazard ratios for
death were 2.37 (95% confidence interval [CI]: 1.51 to 3.72) for the PPM after TAVI group, 2.75 (95% CI: 1.52 to
4.97) for the PPM before TAVI group, and 2.24 (95% CI: 1.62 to 3.09) for the no PPM group.
Conclusions Although prognosis remains impaired compared with an age-, sex-, and origin-matched standardized population,
periprocedural PPM implantation does not seem to affect clinical outcomes adversely among patients undergo-
ing transfemoral TAVI. (J Am Coll Cardiol 2012;60:493–501) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.054Degenerative aortic valve stenosis is mediated by lipid
retention, inflammation, and transformation of the tissue
matrix resulting in calcification of valve leaflets with exten-
sion to the annulus and atrioventricular (AV) groove (1).
From the *Department of Cardiology, Swiss Cardiovascular Center, Bern University
Hospital, Bern, Switzerland; †Clinical Trials Unit, Bern, Switzerland; ‡Department
of Cardiology, Bonn University Hospital, Bonn, Germany; §Department of Cardi-
ology, HELIOS Heart Center, Siegburg, Germany; Department of Anesthesiology,
Bern University Hospital, Bern, Switzerland; and the ¶Department of Cardiology,
Gemeinschaftskrankenhaus Bonn, Bonn, Germany. Dr. Buellesfeld is a consultant
and proctor for Medtronic. Dr. Wenaweser is a proctor and receives honoraria fromOwing to the close spatial proximity of the aortic valve
annulus, AV node, and bundle of His, this disease process
can impair AV conduction and may require implantation of
a permanent pacemaker (PPM) (2). Among patients under-
Medtronic CoreValve and Edwards LifeSciences. Dr. Khattab has received speaker
honoraria and proctor fees from Medtronic CoreValve and Edwards LifeSciences. Dr.
Meier has received research grants from Medtronic and Abbott. Dr. Jüni is an unpaid
member of steering groups and executive committees of trials funded by Abbott
Vascular, Biosensors, Cordis, and Medtronic. Drs. Grube, Boekstegers, and Gerckens
are proctors and consultants for Medtronic. Dr. Windecker has received honoraria
and consultant fees from Edwards LifeSciences and Medtronic CoreValve. Dr. Eberle
494 Buellesfeld et al. JACC Vol. 60, No. 6, 2012
Impact of TAVI-Related Pacemaker Implantation August 7, 2012:493–501going surgical aortic valve re-
placement or transcatheter aortic
valve implantation (TAVI), me-
chanical trauma at the level of
the native valve and the adjacent
subvalvular endocardial region
may affect AV conduction fur-
ther because of indirect mecha-
nisms such as tissue edema and
local inflammation, or direct
pressure necrosis related to the
implantation of the prosthesis or
balloon valvuloplasty in case of
TAVI. Thus, PPM implantation
has been reported in 3% to 9%
(3–8) of patients undergoing surgical aortic valve replace-
ment, with lower rates in the past decade presumably
resulting from improvements in surgical techniques (7,8).
Conversely, PPM implantation rates of up to 40% have
been observed in recently published series among patients
undergoing TAVI (9–19), particularly when using a self-
expanding prosthesis.
Although PPM implantation constitutes a significant
proportion of procedure-related complications among pa-
tients undergoing TAVI, it is widely considered a benign
event as compared with other major adverse cardiac and
cerebrovascular events such as death, stroke, and myocardial
infarction. Notwithstanding, PPM implantation not only
requires an additional procedure, but also results in loss of
physiological AV synchrony and altered hemodynamics and
may predispose a patient to atrial fibrillation and cerebro-
vascular events. Moreover, AV-conduction disturbances
usually are the expression of far advanced underlying cardiac
disease, which may predispose patients to an adverse out-
come, particularly among TAVI patients with frequent
comorbidities and advanced age. To investigate the prog-
nostic impact of TAVI-related PPM implantation, we
compared the long-term clinical outcome of patients requir-
ing PPM implantation after TAVI with that of patients
without the need for PPM implantation, those with a PPM
before TAVI, and an age-, sex-, and origin-based standard-
ized control population.
Methods
Study design and patient population. The study popula-
tion consisted of consecutive patients undergoing trans-
femoral TAVI for treatment of symptomatic native aortic
valve stenosis using the Edwards Sapien/Sapien XT pros-
thesis (ESP; Edwards LifeSciences, Irvine, California) or
the Medtronic CoreValve prosthesis (MCV; Medtronic,
has received honoraria from Medtronic Corevalve. All other authors have reported
that they have no relationships relevant to the contents of this paper to disclose. Drs.
Buellesfeld and Stortecky contributed equally to this work.
Abbreviations
and Acronyms
AV  atrioventricular
CI  confidence interval
ESP  Edwards Sapien/
Sapien XT prosthesis
HR  hazard ratio
MCV  Medtronic
CoreValve prosthesis
PPM  permanent
pacemaker
TAVI  transcatheter aortic
valve implantationManuscript received January 4, 2012; revised manuscript received February 28,
2012, accepted March 19, 2012.Minneapolis, Minnesota) at 2 institutions, Bern University
Hospital, Bern, Switzerland, and Siegburg Heart Center,
Siegburg, Germany. During the enrollment period, Sieg-
burg Heart Center implanted only the MCV, whereas
patients at Bern University were treated with both devices.
Device selection was based on anatomic parameters and
technical characteristics of the prostheses, as described
elsewhere (15). Patients were accepted for TAVI after
consensus obtained by the local heart team consisting of
cardiologists and cardiac surgeons.
The TAVI procedure was performed using percutaneous
femoral access, balloon predilation, and subsequent implan-
tation of the prosthesis under conscious sedation or general
anesthesia. A temporary pacemaker was used for rapid right
ventricular pacing during balloon predilation as well as
during implantation of the ESP and remained in place for
48 h after the procedure unless significant AV conduction
disturbances were observed. Patients were monitored by
continuous electrocardiography for 48 h in an intermediate
care unit. Twelve lead electrocardiograms were obtained
systematically at baseline, during the procedure, and daily
after the procedure until hospital discharge. In case of
procedure-related significant AV-conduction disturbances
defined as high-degree AV block (third-degree or type II
second-degree AV block), new-onset left bundle branch block
with dynamic PR interval prolongation of more than 300 ms,
or atrial fibrillation with inadequate ventricular escape rhythm,
patients underwent PPM implantation.
Patients were categorized into 3 study groups: 1) patients
requiring PPM implantation within 30 days after TAVI
(PPM after TAVI group); 2) patients without PPM im-
plantation up to 30 days before or after the procedure (no
PPM group); and 3) patients with prior PPM implantation
(PPM before TAVI group). The study complied with the
Declaration of Helsinki and was approved by both institu-
tional ethics committees. All patients provided written,
informed consent.
Data collection and endpoints. Adverse events were as-
sessed in the hospital, and regular clinical follow-up was
performed at 30 days and 12 months by means of a clinic
visit or a standardized telephone interview. All suspected
events were adjudicated by an unblinded clinical event
committee consisting of cardiac surgeons and interventional
cardiologists. Baseline clinical and procedural characteristics
and all follow-up data were entered into a dedicated
database, held at an academic clinical trials unit (Clinical
Trials Unit Bern, Bern University Hospital, Bern, Switzer-
land) responsible for central data audits and maintenance
of the database. The primary study endpoint was all-
cause mortality at 12 months. Secondary endpoints in-
cluded stroke, transient ischemic attack, myocardial in-
farction, as well as the composite of these major adverse
cardiac events. Observed rates of all-cause mortality at 12
months were compared with an age-, sex-, and country-
s
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were adjudicated according to the Valve Academic Re-
search Consortium criteria (20).
Definitions. Acute device success was considered to be
uccessful vascular access, delivery, and deployment of the
evice and successful retrieval of the delivery system, correct
osition of the device with adequate hemodynamic perfor-
ance (mean aortic valve gradient20 mm Hg and absence
of moderate or severe prosthetic valve aortic regurgitation)
in the proper anatomic location with only 1 device used.
Stroke was defined as rapid onset of a neurologic deficit of
24 hours’ duration or longer or an event necessitating either
therapeutic intervention or documentation of a new intra-
cranial defect using neuroimaging. Transient ischemic at-
tack was defined as new focal neurological deficit with rapid
symptom resolution within 24 h and without evidence of
tissue injury in neuroimaging studies. Periprocedural myo-
cardial infarction was defined as ischemic symptoms or signs
combined with elevated cardiac biomarkers (peak value
more than 10 times the upper reference limit or a peak value
more than 5 times the upper reference limit with new
Figure 1 Diagram Showing Patient Flow
Diagram showing the flow of patients enrolled into the present study, including rec
maker before transcatheter aortic valve implantation (TAVI) (PPM before TAVI), pat
patients without permanent pacemaker implantation (no PPM); and completeness
PPM implantation on days 2, 3, and 7 prior to the TAVI procedure.pathologic Q waves in at least 2 contiguous leads) within
72 h after the index procedure.
Statistical analysis. Patient demographics and procedural
and postprocedural data were collected prospectively and
were entered in a dedicated database held at Clinical Trials
Unit Bern, Bern University Hospital, Bern, Switzerland. All
statistical analyses were performed by statisticians of an
academic clinical trials unit (D.H. and P.J., Clinical Trials
Unit Bern, Bern University Hospital, Bern, Switzerland)
using Stata 12 software (StataCorp LP, College Station,
Texas). Continuous variables are presented as mean  SD
and are compared by means of analysis of variance. Cate-
gorical data are expressed as frequency and percentages and
are compared using the chi-square and Fisher exact tests.
Survival curves were constructed for each endpoint accord-
ing to the Kaplan-Meier method and were compared by
Cox regression, and the corresponding hazard ratios (HRs,
with 95% confidence intervals [CIs]) with p values were
reported at the 30-day and 12-month follow-up visits,
respectively (so-called crude Cox regression analyses). End-
points with 0 events in 1 or more treatment groups were
nt; allocation to the respective study group—patients with permanent pace-
ith new permanent pacemaker implantation after TAVI (PPM after TAVI), and
ow-up at 30 days and 12 months. *Including 3 patients with TAVI-associatedruitme
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95% confidence intervals) with Fisher exact tests and p
values are reported at 30 days and 12 months of follow-up,
respectively. The so-called adjusted Cox regression analyses
of end points were performed by multinomial probit regres-
sion propensity score adjustment as follows (21). First, we
fitted a multinomial probit regression model on the depen-
dent variable treatment group (no PPM, PPM before
TAVI, or PPM after TAVI) and the independent variables
age, sex, type of prosthesis, hypertension, renal failure, prior
stroke, and atrial fibrillation. Second, we extracted the
estimated probability for each patient to fall into the no
PPM group, based on these 7 independent variables. Third,
this probability was entered as a propensity score covariate
(degrees of freedom: 1) into the adjusted Cox regression
analyses, and we report the adjusted HRs comparing treat-
ment groups. Note that adjusted Cox regression analyses
were possible only for end points with at least 1 event in
each treatment group. Standardized mortality ratios were
calculated for each treatment group, for males, for females,
and for all patients separately using indirect standardization
(i.e., compared with the Swiss and German national life
tables per age and gender). All p values and confidence
intervals are 2-sided. A p value 0.05 was considered
tatistically significant.
esults
etween August 2007 and March 2010, 353 consecutive
atients underwent transfemoral TAVI at 2 institutions,
ith follow-up data available for 352 patients (99.7%) (Fig. 1).
total of 207 patients (58.6%) required no PPM during
ollow-up (no PPM group), and 48 patients (13.6%) already
ad a PPM before the procedure (PPM before TAVI
Figure 2 Frequency Distribution of Permanent Pacemaker Impl
The bars left of the beige bar indicate preventive pacemaker implantation beforeroup). The remaining 98 patients (27.8% of the overall
tudy population, 32.1% of patients without PPM before
AVI) received a PPM within 30 days of TAVI (PPM after
AVI group, 29.2% of patients with MCV, 14.7% of
atients with ESP). The indications for TAVI-related PPM
mplantation included high-degree AV block (62.2%), new-
nset left bundle branch block with PR interval prolonga-
ion (21.4%), and slow atrial fibrillation (16.3%). Three
atients included in the PPM after TAVI group had
eceived a PPM immediately before undergoing TAVI in a
rophylactic fashion because of the presence of left bundle
ranch block with marked PR interval prolongation in 2
ases and right bundle branch block with PR prolongation
n 1 patient. The median preprocedural interval from
acemaker implantation to the index TAVI procedure in
hese patients was 3 days (range: 2 to 7 days). All 3 patients
ad complete AV block after the procedure. Postprocedural
PM implantation was performed at a median interval of 3
ays (range: 0 to 22 days) (Fig. 2).
atient population. Baseline characteristics according to
PM group are summarized in Table 1. The mean patient
ge was 82.6  6.1 years, without significant differences
etween groups. Among patients in the PPM before TAVI
roup, comorbidities were more common compared with
he other 2 groups, including presence of hypertension
PPM before TAVI group: 93.8%, no PPM group: 72.9%,
PM after TAVI group: 73.5%, p 0.004), coronary artery
isease (77.1%, 52.7%, and 58.2%, respectively, p  0.009),
rior myocardial infarction (31.3%, 14.5%, and 16.3%,
espectively, p  0.02), prior percutaneous coronary inter-
ention (37.5%, 15.5%, and 19.4%, respectively, p 0.002),
enal failure (35.4%, 19.8%, and 19.4%, respectively, p 
.049), and atrial fibrillation (43.8%, 22.7%, and 20.4%,
ion Over Time
theter aortic valve implantation. Abbreviation as in Figure 1.antat
tranca
dial infa
p
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EuroSCORE was somewhat higher in the PPM before
TAVI group (28.4  15.9%) compared with the no PPM
and PPM after TAVI groups together (24.4  14.9%, p 
0.09). There were no differences between the groups with
regard to baseline symptom status and echocardiographic
characteristics, including aortic valve area, mean valve gra-
dient, and left ventricular ejection fraction.
Procedural results. Procedural characteristics and results
are summarized in Table 2. All patients underwent
transfemoral TAVI with either the MCV (90.4%, 319 of
353) or the ESP (9.6%, 34 of 353) prosthesis. Acute
Baseline Clinical and Echocardiographic CharacteristicsTable 1 Baseline Clinical and Echocardiographic Characteristic
No PPM (n  207) PP
Age (yrs) 82.63 6.22
Female 127 (61.4%)
Comorbidities
Hypertension 151 (72.9%)
Current smoker 27 (13.0%)
Diabetes 49 (23.7%)
Coronary artery disease 109 (52.7%)
Pulmonary hypertension 42 (20.3%)
Renal failure 41 (19.8%)
Peripheral vasc. disease 37 (17.9%)
Prior MI 30 (14.5%)
Prior PCI 32 (15.5%)
Prior CABG 39 (18.8%)
Prior stroke 13 (6.3%)
Atrial fibrillation 47 (22.7%)
Symptoms
NYHA functional class III/IV 146 (71.6%)
Risk assessment
Log EuroSCORE 22.77 14.42 (200%)
Echocardiography before TAVI
LVEF, % 52.21 14.82 (207%)
Mean gradient, mm Hg 45.03 16.62 (173%)
AVA, cm2 0.62 0.18 (177%)
Values are mean  SD, n (%), mean  SD (%).
CABG  coronary artery bypass graft; LVEF  left ventricular ejection fraction; MI  myocar
ermanent pacemaker; TAVI  transcatheter aortic valve implantation.
Procedural Data and Acute Echocardiographic OutcomesTable 2 Procedural Data and Acute Echocardiographic Outcom
No PPM (n  207)
Procedure
Acute device success 200 (96.6%)
Conversion to surgery 1 (0.5%)
Valve in valve/sequential 4 (1.9%)
Type of prosthesis implanted
CoreValve 180 (87.0%)
Edwards 27 (13.0%)
After TAVI
Mean gradient, mm Hg 8.56 4.55 (188%)
Aortic regurgitation (2 or 3 grade) 49 (25.5%)
AVA, cm2 1.69 0.46 (139%)Values are n (%) or mean  SD (%).
Abbreviations as in Table 1.device success was similar in all 3 groups, ranging from
96.6% to 97.9%. In 1 patient, acute conversion to surgery
was required after embolization of an ESP. Myocardial
wire perforation occurred in 1 patient before device
implantation, and sequential double-valve implantation
was required in 9 patients to correct misplaced or
functionally unsatisfactory results after implantation of
the first prosthesis.
Clinical outcomes. Clinical outcomes at 30 days and 12
months of follow-up are shown in Table 3. All-cause
mortality at 30 days and 12 months was 6.2% and 19.0%,
respectively, without differences among the no PPM group
fore TAVI (n  48) PPM After TAVI (n  98) p Value
2.61 5.73 82.53 5.99 0.99
24 (50.0%) 52 (53.1%) 0.21
45 (93.8%) 72 (73.5%) 0.004
2 (4.2%) 14 (14.3%) 0.17
15 (31.3%) 28 (28.6%) 0.45
37 (77.1%) 57 (58.2%) 0.01
16 (33.3%) 30 (30.6%) 0.053
17 (35.4%) 19 (19.4%) 0.049
8 (16.7%) 25 (25.5%) 0.25
15 (31.3%) 16 (16.3%) 0.021
18 (37.5%) 19 (19.4%) 0.003
14 (29.2%) 29 (29.6%) 0.067
4 (8.3%) 10 (10.2%) 0.48
21 (43.8%) 20 (20.4%) 0.005
40 (83.3%) 77 (81.1%) 0.086
7 15.91 (47%) 27.76 15.23 (98%) 0.01
0 14.07 (48%) 49.27 16.37 (98%) 0.15
2 17.12 (40%) 45.32 14.97 (76%) 0.32
4 0.18 (41%) 0.62 0.17 (83%) 0.83
rction; NYHA  New York Heart Association; PCI  percutaneous coronary intervention; PPM 
efore TAVI (n  48) PPM After TAVI (n  98) p Value
47 (97.9%) 95 (96.9%) 1.00
0 (0.0%) 0 (0.0%) 1.00
2 (4.2%) 2 (2.0%) 0.52
0.03
46 (95.8%) 93 (94.9%)
2 (4.2%) 5 (5.1%)
13 4.28 (46%) 8.92 3.84 (96%) 0.06
8 (16.7%) 20 (20.6%) 0.38
66 0.37 (39%) 1.70 0.53 (69%) 0.90s
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versus no PPM group: 1.18, 95% confidence interval [CI]
0.59 to 2.36), and PPM after TAVI group (19.4%, adjusted
HR versus no PPM group: 1.06, 95% CI: 0.60 to 1.84)
(Fig. 3). Strokes occurred in 2.8% of patients at 30 days and
12 months. The composite endpoint of death, stroke, or
myocardial infarction at 12 months was 20.4% (no PPM),
22.9% (PPM before TAVI), and 21.4% (PPM after TAVI,
p  0.97). The rates for stroke, transient ischemic attack,
and myocardial infarction were low, limiting the precision
of estimates of HRs for these parameters (Table 3).
Comparing the HRs for death as well as the composite
endpoints death or stroke and death, stroke, and myocardial
infarction between PPM after TAVI and no PPM patients,
respectively, we observed similar risks in crude and adjusted
analyses. Results also were consistent among most sub-
groups, with the exception of atrial fibrillation, in which the
subgroup patients with PPM after TAVI compared with
those with no PPM trended to have a higher risk of death,
stroke, and myocardial infarction in the adjusted analyses
(HR: 2.26, 95% CI: 0.85 to 5.98, p  0.08 for interaction).
Comparing the observed mortality of all study groups
with an age, gender, and region-matched population,
adjusted HRs for death were 2.24 (95% CI: 1.62 to 3.09)
for the no PPM group, 2.75 (95% CI: 1.52 to 4.97) for
the PPM before TAVI group, and 2.37 (95% CI: 1.51 to
3.72) for the PPM after TAVI group, with a trend for the
highest risk among patients in the PPM before TAVI
group (Fig. 4).
Discussion
The principal findings of the present study can be summa-
rized as follows: 1) AV-conduction disturbances requiring
PPM implantation after TAVI remain common, particu-
larly after implantation of the self-expanding MCV pros-
thesis; 2) all-cause mortality and other major cardiac and
cerebrovascular events were observed with similar frequency
through 12 months among patients requiring PPM implan-
tation after TAVI compared with patients without the need
of PPM and those with a PPM before TAVI; and 3)
regardless of PPM implantation, all-cause mortality in-
creased more than 2-fold among patients with severe aortic
stenosis who were undergoing TAVI as compared with an
age-, sex-, and region-matched standardized population.
PPM implantation after transfemoral TAVI seems rather
innocuous compared with other adverse events complicating
TAVI. This finding is of importance because PPM implan-
tation among patients undergoing TAVI is not uncommon.
Recently reported PPM implantation rates range from 5%
to 40% (9–19), with an increased incidence among patients
receiving the self-expanding MCV prosthesis (18% to 43%)
(10,12–15,18,19) as compared with patients treated with
the balloon-expandable ESP (5% to 22%) (9–12,15–17,19).
Differences in device designs may explain this finding, such
as a deeper extension of the stent frame into the leftCl
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of the MCV prosthesis, maintaining a steady radial force on
the annular and subendocardial tissue. In addition, because
of the lack of established and uniformly applied criteria for
TAVI-related PPM implantation as well as heterogeneous
implantation techniques (i.e., intended target depth of
prosthesis implant, balloon and device sizing, and so on),
the currently reported PPM rates differ substantially among
different sites and studies. In our study, we observed a
pacemaker rate of 27.8% (14.7% for ESP, 29.2% for MVP),
which remains high but is well in line with previous reports.
The predominant indication of TAVI-related PPM im-
plantation was the development of a complete AV block,
similarly consistent with previous findings (14).
Several predictors of severe AV-conduction disturbances
necessitating PPM implantation after TAVI have been
described, including right bundle branch block at baseline,
deep valve implantation (6 mm below the annular plane),
increased septal wall thickness, noncoronary cusp thickness,
and degree of calcification (12,22–24). However, the actual
mechanisms are not understood fully. Left bundle branch
block is the most commonly observed conduction disorder
after TAVI (12,25), most likely induced by direct mechan-
ical injury to the subvalvular region, which houses critical
parts of the left-sided conduction system. Consequently,
patients with pre-existing right bundle branch block are
at particular risk of having complete heart block after
TAVI. Prophylactic PPM implantation before TAVI in
Figure 3 Cumulative Incidence of All-Cause Mortality Through
The blue line represents outcomes of patients with permanent pacemaker implant
maker implantation after TAVI, and the green line represents patients without perm
abbreviations as in Figure 1.elected patients with predisposing electrocardiographicfindings therefore is common practice in several centers and
amounted to 3% of all TAVI-related PPM implantations in
the present study.
Patients undergoing TAVI are a priori characterized by
an exceptionally high risk profile because of the presence of
severe cardiac pathological features in conjunction with
other noncardiac comorbidities. Taking into account that
the presence of AV-conduction disturbances is an expres-
sion of the severity of underlying cardiac disease predictive
of adverse outcome (26), the occurrence of a conduction
defect among patients undergoing TAVI theoretically may
suggest a particularly harmful event. Indeed, in the present
study, patients with previous PPM implantation before
TAVI had a higher risk profile, with notable differences in
various baseline characteristics, including hypertension, cor-
onary artery disease, myocardial infarction, prior percutane-
ous coronary intervention, renal failure, and atrial fibrilla-
tion compared with patients without a history of PPM
implantation. Notwithstanding, clinical outcome in terms of
all-cause mortality through 12 months did not differ signif-
icantly among the 3 groups, regardless of the pacing status
and compare favorably, with reported rates ranging from
24% to 31% in this type of high-risk population undergoing
TAVI (16,17,27,28). Compared with a sex- and age-
matched standardized population, patients with severe aor-
tic stenosis undergoing transfemoral TAVI still had an
increased risk of mortality that seemed to be more than
twice as high as that in the general population, presumably
r According to Study Group
before TAVI, the red line represents patients with the need for permanent pace-
t pacemaker implantation. CI  confidence interval; HR  hazard ratio; other1 Yea
ation
anenbecause of the increased baseline risk profile. Interestingly,
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significantly higher baseline risk than the other 2 study
groups, showed the highest relative risk increase at 12
months in the present study. An extended follow-up period
beyond 12 months may be necessary to reveal a significant
difference for this particular population. Conversely, we did
not find any indicators that patients without a history of
PPM implantation who required permanent pacing after
TAVI exhibit a different prognosis compared with patients
without the need for pacing, which constitute 2 groups with
similar baseline characteristics. It therefore may be specu-
lated that spontaneous occurrence of AV-conduction disor-
ders constitutes an indicator for adverse outcome driven by
the extent of underlying cardiac disease, whereas procedure-
related AV-conduction disorders after mechanical stress, as
observed during various steps of the TAVI procedure,
confers a more favorable long-term prognosis.
Several additional aspects associated with TAVI-related
PPM implantations deserve consideration. PPM implanta-
tion adds technical complexity and considerable cost and
may result in prolonged hospitalization (6). Apart from this,
the impact of TAVI-related PPM implantation on out-
comes such as functional patient status, atrial and ventric-
ular remodeling, and rhythm profile deserves further de-
Figure 4 Standardized Mortality Ratios With 95% CIs per Study
Standardized mortality ratio (SMR) is the ratio of observed to expected number of
group had higher rates of death than expected for an age-, sex-, and country-ma
Figures 1 and 3.tailed evaluation. Moreover, the implantation of single leadpacemakers with ventricular pacing modes in patients older
than a certain age limit, which is common practice with
supporting evidence (29), may be called into question in the
TAVI patient population in view of the preload-dependent
filling properties of the hypertrophic and restrictive ventri-
cles, particularly in the presence of preserved atrial function.
Study limitations. Most patients enrolled in this study
received the self-expanding MCV, whereas only 10% were
treated with a balloon-expandable ESP. Therefore, the
results may be affected by this unequal distribution, al-
though we corrected for this confounder in adjusted analy-
ses. In addition, only patients with transfemoral TAVI have
been included in the present analysis, and similar studies
may be necessary for alternative access routes such as
transapical, subclavian, or direct aortic access. Furthermore,
this study was not designed to prove the obvious benefit of
pacing in patients with severe TAVI-related conduction
disorders, comparing patients receiving a PPM versus those
not receiving a PPM under this condition, but rather to
analyze the impact of PPM implantation in patients with
TAVI-related conduction disorders compared with patients
without periprocedural PPM implantation resulting from an
absence of TAVI-related PPM-requiring conduction disor-
ders. Finally, one carefully has to interpret the negative
up for the Overall Population and According to Sex
comparing study patients with a reference population. SMR 1 indicates the
(Switzerland or Germany) reference population. Abbreviations as inGro
deaths
tchedresults of the present study in the context of the event rates
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certainly has to be confirmed in a larger patient population
with a prolonged follow-up period.
Conclusions
Although prognosis remains impaired compared with an
age-, sex-, and origin-matched standardized population,
periprocedural PPM implantation does not seem to affect
clinical outcomes adversely among patients undergoing
transfemoral TAVI.
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